Satraplatin - Yakult Honsha
Alternative Names: BMS 182751; BMY 45594; JM-216; OrplatnaLatest Information Update: 12 Jan 2024
At a glance
- Originator Bristol-Myers Squibb; Johnson Matthey; The Institute of Cancer Research
- Developer Agennix AG; Shanghai Jiao Tong University; Yakult Honsha
- Class Antineoplastics; Cyclohexylamines; Platinum complexes
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer; Squamous cell cancer
- Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 09 Apr 2021 No development reported - Phase-I/II for Squamous cell cancer (Inoperable/Unresectable, Late-stage disease) in Japan (PO)
- 28 Feb 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Neoadjuvant therapy) in China (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Second-line therapy or greater) in Japan (PO, Capsule)